NEW YORK, Aug. 23 – Rosetta Inpharmatics has licensed its Resolver gene expression data analyzer to functional genomics company Europroteome, Rosetta said on Thursday.
Europroteome, based in Hennigsdorf, Germany, will use the system to help it manage and analyze genomic data for its research in epithelial cancers.
Terms of the agreement were not disclosed.
Earlier this month, Rosetta and Agilent Technologies, which exclusively distributes the Resolver system, said that Germany’s Max Planck Institutes for Molecular Genetics, Infection Biology, and Molecular Plant Physiology would act as European demonstration sites for the Resolver system and for Agilent’s DNA Microarray Scanner.
Rosetta, based in Kirkland, Wash., also said it has launched a satellite customer service operation in Europe, housed at Agilent Technologies' facility in Amsterdam.
Bill Buffington, vice president and general manager of Agilent Technologies' life sciences division, said at the time that the deal with the research institutes would “allow greater access to the Rosetta Resolver system and Agilent's new open-systems-based DNA Microarray Scanner for prospective users in Europe.”